Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr;9(4):2884-2894.
doi: 10.21037/tcr.2020.03.36.

Type 2 diabetes mellitus does not increase the risk of multiple myeloma: a systematic review and meta-analysis

Chenlu Zhang #  1 , Yuou Sha #  2 , Haiyan Liu #  1 , Dan Guo  1 , Yijing Jiang  1 , Lemin Hong  1 , Lili Shi  3 , Hongming Huang  1
Affiliations

Type 2 diabetes mellitus does not increase the risk of multiple myeloma: a systematic review and meta-analysis

Chenlu Zhang et al. Transl Cancer Res. 2020 Apr.

Abstract

Background: Epidemiological studies have shown that patients with type 2 diabetes mellitus (T2DM) are at a higher risk of secondary tumors. However, no consensus has been made about whether T2DM can increase the risk of multiple myeloma (MM).

Methods: We searched the databases of PubMed, Cochrane Library and EMBASE and cross-checked the bibliography. Data quality was assessed using the Newcastle-Ottawa scale (NOS). Heterogeneity was calculated as the odds ratio (OR) using a random-effects model. Data were analyzed using Stata version 12.0 software.

Results: A total of 13 articles were selected into this meta-analysis. Initially, we found that diabetic patients had a higher risk of myeloma than non-diabetic patients (OR =1.60, 95% CI: 1.13-2.26, I2=98%, P=0.000). But the data in these articles were highly heterogeneous (I2>75%). Therefore, eight of the included articles showed a moderate heterogeneity (I2=71.6%). We used Galbraith heterogeneity map to analyze the causes of heterogeneity. Two articles with high heterogeneity were excluded. Then, we found the heterogeneity of the left six articles was reduced from moderate to mild (I2=45.9%, P=0.100). The final results of this meta-analysis showed that T2DM was not a risk factor for increased incidence of MM (OR =1.05, 95% CI: 0.83-1.33, I2=45.9%, P=0.100). Also, the subgroup analysis (case-control studies vs. cohort studies) showed no statistical difference (OR =1.19, 95% CI: 0.76-1.85, I2=1%, P=0.364; OR =1.00, 95% CI: 0.75-1.33, I2=71.2%, P=0.031; respectively).

Conclusions: T2DM is not a risk factor for the increased incidence of MM, a finding that should be validated with more strictly designed randomized controlled trials (RCTs).

Keywords: Meta-analysis; carcinogenic risk; multiple myeloma (MM); type 2 diabetes mellitus (T2DM).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2020.03.36). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Results of the literature search.
Figure 2
Figure 2
Odds ratio (OR) of myeloma for patients with diabetes compared with control subjects (patients without diabetes).
Figure 3
Figure 3
Sensitivity analysis of each included study. (A) The first analysis; (B) the second analysis; (C) the third analysis; (D) the forth analysis.
Figure 4
Figure 4
Galbraith heterogeneity of each included study.
Figure 5
Figure 5
Sensitivity analysis of each included study.
Figure 6
Figure 6
Odds ratio (OR) of myeloma for patients with diabetes compared with control subjects (patients without diabetes).
Figure 7
Figure 7
Odds ratio (OR) of myeloma for patients with diabetes in different study types.
Figure 8
Figure 8
Begg’s funnel plots of the publication bias.
Figure S1
Figure S1
Sensitivity analysis of each included study.
See this image and copyright information in PMC

References

    1. Thordardottir M, Lindqvist EK, Lund SH, et al. Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study. Blood Adv 2017;1:2186-92. 10.1182/bloodadvances.2017007609 - DOI - PMC - PubMed
    1. Michels TC, Petersen KE. Multiple Myeloma: Diagnosis and Treatment. Am Fam Physician 2017;95:373-83. - PubMed
    1. Uckun FM, Qazi S, Demirer T, et al. Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma. EBioMedicine 2019;39:612-20. 10.1016/j.ebiom.2018.12.004 - DOI - PMC - PubMed
    1. Selvin E, Parrinello CM, Sacks DB, et al. Trends in prevalence and control of diabetes in the United States, 1988-1994 and 1999-2010. Ann Intern Med 2014;160:517-25. 10.7326/M13-2411 - DOI - PMC - PubMed
    1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1789-858. 10.1016/S0140-6736(18)32279-7 - DOI - PMC - PubMed